Ra Pharmaceuticals Inc., of Cambridge, Mass., plans to present the design of its phase II trial testing RA-101495 SC, an inhibitor of complement component 5, in patients with generalized myasthenia gravis at the 70th Annual American Academy of Neurology in Los Angeles next month.